Breaking News Instant updates and real-time market news.

AAXN

Axon

$27.92

1.08 (4.02%)

07:35
02/15/18
02/15
07:35
02/15/18
07:35

Axon receives orders for 12,000 TASER Smart Weapons

Axon received multiple orders for its TASER X26P and TASER X2 Smart Weapons. These orders were received in 4Q17 and 1Q18 and are expected to have shipped by the end of 1Q18. Significant orders from domestic agencies include Orlando Police Department with 800 X2s, TASER 60, Indianapolis Metropolitan Police Department with 750 X26Ps, Broward County Sheriff's Office with 725 X2s, and Houston Police Department with 600 X2s.

  • 27

    Feb

  • 21

    Mar

AAXN Axon
$27.92

1.08 (4.02%)

04/06/17
IMPC
04/06/17
NO CHANGE
Target $25
IMPC
In-Line
Taser shift to 'Axon' brings SaaS promise, challenges, says Imperial Capital
Imperial Capital analyst Jeff Kessler said Taser's name change to Axon is a "bold move" that reflects the company's vision of becoming a Software-as-a-Service security company, which could yield higher and faster growing recurring revenue down the line. However, the company will also have to face SaaS realities, such as significant investment, new pricing models, revised sales and marketing plans and new partner models, said Kessler, who keeps an In-Line rating and $25 price target on the shares.
08/10/17
JPMS
08/10/17
NO CHANGE
Target $32
JPMS
Overweight
Axon selloff yesterday overdone, says JPMorgan
JPMorgan analyst Mark Strouse views yesterday's 9% post-earnings selloff in shares of Axon as overdone. The company has "strong visibility" into gross margin improvement during the second half of 2017, Strouse tells investors in a research note. He maintains an Overweight rating on Axon with a $32 price target.
11/16/17
MAXM
11/16/17
NO CHANGE
Target $4
MAXM
Buy
Digital Ally price target lowered to $4 from $9 at Maxim
Maxim analyst Brian Kinstlinger lowered his price target on Digital Ally (DGLY) to $4, saying Q3 results showed revenue remains depressed while the low $316k cash balance means the company will have to raise cash before year-end. Kinstlinger keeps his Buy rating, noting the company's strategic alternatives review as well as its patent infringement suit against Axon (AAXN) that could produce shareholder value, but says it is difficult to predict the outcome of litigation.
11/17/17
CHLM
11/17/17
NO CHANGE
Target $30
CHLM
Buy
Craig-Hallum more confident in Axon after analyst day
Craig-Hallum analyst Steven Dyer said that after attending Axon's analyst day meeting he is more confident in management's ability to drive profitable growth, noting that they highlighted not only their sales growth but their margin expansion opportunities. Dyer reiterates his Buy rating and $30 price target on Axon shares.

TODAY'S FREE FLY STORIES

GKOS

Glaukos

$71.40

0.31 (0.44%)

05:46
04/26/19
04/26
05:46
04/26/19
05:46
Hot Stocks
Glaukos enters collaboration, distribution agreement with Santen »

Santen Pharmaceutical and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 05

    Jun

  • 13

    Nov

NITE

Nightstar Therapeutics

$25.61

0.08 (0.31%)

, BIIB

Biogen

$229.78

5.46 (2.43%)

05:43
04/26/19
04/26
05:43
04/26/19
05:43
Hot Stocks
Nightstar: ISS, Glass Lewis recommend holders vote 'FOR' deal with Biogen »

Nightstar Therapeutics…

NITE

Nightstar Therapeutics

$25.61

0.08 (0.31%)

BIIB

Biogen

$229.78

5.46 (2.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 01

    May

  • 04

    May

  • 29

    May

SNY

Sanofi

$41.27

-0.2 (-0.48%)

05:41
04/26/19
04/26
05:41
04/26/19
05:41
Earnings
Sanofi backs FY19 business EPS growth of 3%-5% at CER »

Sanofi continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 28

    Apr

  • 04

    May

  • 08

    May

  • 31

    May

  • 26

    Jun

SNY

Sanofi

$41.27

-0.2 (-0.48%)

05:39
04/26/19
04/26
05:39
04/26/19
05:39
Earnings
Sanofi reports Q1 business EPS EUR 1.42 vs. EUR 1.28 »

Reports Q1 revenue EUR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 28

    Apr

  • 04

    May

  • 08

    May

  • 31

    May

  • 26

    Jun

AZN

AstraZeneca

$39.07

0.35 (0.90%)

05:36
04/26/19
04/26
05:36
04/26/19
05:36
Earnings
AstraZeneca backs FY19 core EPS view of $3.50-$3.70 »

Backs FY19 product sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    May

  • 07

    May

  • 31

    May

  • 20

    Jun

AZN

AstraZeneca

$39.07

0.35 (0.90%)

05:32
04/26/19
04/26
05:32
04/26/19
05:32
Earnings
AstraZeneca reports Q1 reported EPS 47c, consensus 42c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    May

  • 07

    May

  • 31

    May

  • 20

    Jun

PRO

Pros Holdings

$45.06

-0.25 (-0.55%)

05:29
04/26/19
04/26
05:29
04/26/19
05:29
Recommendations
Pros Holdings analyst commentary  »

Pros Holdings price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

ILMN

Illumina

$318.91

4.47 (1.42%)

05:27
04/26/19
04/26
05:27
04/26/19
05:27
Recommendations
Illumina analyst commentary at Piper Jaffray »

Illumina earnings selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 31

    May

  • 06

    Aug

  • 03

    Sep

ALGT

Allegiant Travel

$139.70

6.33 (4.75%)

05:22
04/26/19
04/26
05:22
04/26/19
05:22
Recommendations
Allegiant Travel analyst commentary at Imperial Capital »

Allegiant Travel price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

NFLX

Netflix

$368.20

-5.99 (-1.60%)

05:19
04/26/19
04/26
05:19
04/26/19
05:19
Recommendations
Netflix analyst commentary at Imperial Capital »

Imperial trims Netflix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

05:16
04/26/19
04/26
05:16
04/26/19
05:16
Recommendations
Amazon.com analyst commentary at Piper Jaffray »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 22

    May

  • 03

    Jun

SBUX

Starbucks

$77.07

0.65 (0.85%)

05:11
04/26/19
04/26
05:11
04/26/19
05:11
Downgrade
Starbucks rating change at Wells Fargo »

Starbucks downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

, ONCE

Spark Therapeutics

$111.40

0.73 (0.66%)

05:10
04/26/19
04/26
05:10
04/26/19
05:10
Hot Stocks
Roche, Spark Therapeutics withdraw, refile premerger notification »

Roche (RHHBY) and Spark…

RHHBY

Roche

$0.00

(0.00%)

ONCE

Spark Therapeutics

$111.40

0.73 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 03

    May

  • 04

    May

  • 28

    May

  • 31

    May

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

VCRA

Vocera

$31.31

0.36 (1.16%)

05:10
04/26/19
04/26
05:10
04/26/19
05:10
Recommendations
Vocera analyst commentary at Piper Jaffray »

Vocera positioned for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 28

    May

  • 05

    Jun

ESPR

Esperion

$43.02

1.14 (2.72%)

05:06
04/26/19
04/26
05:06
04/26/19
05:06
Upgrade
Esperion rating change  »

Esperion upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 07

    May

MDCO

The Medicines Co.

$29.84

0.37 (1.26%)

05:05
04/26/19
04/26
05:05
04/26/19
05:05
Upgrade
The Medicines Co. rating change  »

The Medicines Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 08

    May

RS

Reliance Steel

$91.29

2.46 (2.77%)

05:03
04/26/19
04/26
05:03
04/26/19
05:03
Downgrade
Reliance Steel rating change  »

Reliance Steel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

TAL

TAL Education

05:02
04/26/19
04/26
05:02
04/26/19
05:02
Downgrade
TAL Education rating change  »

TAL Education downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASAZY

Assa Abloy

$0.00

(0.00%)

05:01
04/26/19
04/26
05:01
04/26/19
05:01
Downgrade
Assa Abloy rating change at Jefferies »

Assa Abloy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

BKU

BankUnited

$36.10

-0.39 (-1.07%)

05:00
04/26/19
04/26
05:00
04/26/19
05:00
Downgrade
BankUnited rating change  »

BankUnited downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

TIGO

Millicom

$57.40

-1.25 (-2.13%)

04:59
04/26/19
04/26
04:59
04/26/19
04:59
Upgrade
Millicom rating change  »

Millicom upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITW

Illinois Tool Works

$151.26

-5.52 (-3.52%)

04:56
04/26/19
04/26
04:56
04/26/19
04:56
Upgrade
Illinois Tool Works rating change  »

Illinois Tool Works…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

AXTA

Axalta Coating

$26.71

0.21 (0.79%)

04:55
04/26/19
04/26
04:55
04/26/19
04:55
Downgrade
Axalta Coating rating change  »

Axalta Coating downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

KRP

Kimbell Royalty Partners

$18.00

0.02 (0.11%)

04:55
04/26/19
04/26
04:55
04/26/19
04:55
Conference/Events
Kimbell Royalty Partners management to meet with TD Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

CYAD

Celyad

$20.60

(0.00%)

04:55
04/26/19
04/26
04:55
04/26/19
04:55
Conference/Events
Celyad management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 05

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.